Galway, Ireland 4th May 2023 OmniSpirant is excited to announce the appointment of Andy Fisher to its board of directors. For nearly 20 years, Andy held leadership positions at United Therapeutics Corporation, a global biotechnology company focused on chronic and life-threatening conditions in areas of unmet medical need. Most recently, he was Chief Strategy Officer [...]

PRESS RELEASE We are excited to progress the development of OS001 for CF in collaboration with Prof Lorraine Martin and Dr Lisa Douglas in Queen's University Belfast. Funding support from Emily's Entourage in the USA and The CF Trust in the UK is matched by their scientific expertise which will help to shape further exciting [...]

PRESS RELEASE OmniSpirant Limited are delighted and honoured to announce the launch of INSPIRE, a €12.8 million lung cancer project funded by Horizon Europe. In one of the largest ever grants for preclinical research in lung cancer, OmniSpirant in collaboration with our European partners spanning across biotechnology, medical devices, cancer research, academia and patient advocacy, [...]

StartUs insights analysis of the global respiratory drug development landscape highlights OmniSpirant's inhaled regenerative gene therapy platform: Omnispirant explores Inhaled Gene Therapy In the last decade, advances in gene sequencing and gene editing have made gene therapy more feasible than ever before. For the treatment of respiratory diseases, gene therapy offers a way to correct [...]

Pictured from left to right: Dr Janusz Krawczyk, Dr Róisín Dwyer, Prof John Laffey, Dr Ronan MacLoughlin, Gerry McCauley, Dr Daniel O’Toole and Dr Katie Gilligan ​ NUI Galway, OmniSpirant Limited and Aerogen Limited have been awarded major funding to develop a new aerosol treatment that will transform respiratory medicine, with potential benefits across acute [...]